CClinicalTrials.gg
RecruitingNCT05998551Updated Aug 21, 2023

Single Shot Intrathecal Analgesia in Vaginal Delivery

An interventional study of Dexmedetomidine and Fentanyl in Effectiveness of Single Shot Intra-thecal Analgesia in Multiparous Women Scheduled for Normal Vaginal Delivery, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to female participants aged 22 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jan 2023, registered Jun 2023).
  • Started Jan 2023; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
22 Years to 45 Years
Sex
Female
01

Study summary

Effectiveness of single shot intra-thecal analgesia in multiparous women scheduled for normal vaginal delivery

Read the detailed description

Labor is a physiological and natural process, as well as a complicated and subjective experience.Except for a few women, childbirth is unquestionably a painful experience. Women's understanding of delivery's pain is influenced by various factors, making each experience special. As opposed to other painful life events, labor pain consistently ranks high on the pain rating scale.

In this study ,the investigators are going to investigate the effectiveness and safety of intrathecal analgesia for labour using bupivacaine with fentanyl or dexmedetomidine.

02

Conditions studied

  • Effectiveness of Single Shot Intra-thecal Analgesia in Multiparous Women Scheduled for Normal Vaginal Delivery

Browse trials for

03

In context

Agnosia

1,190 studies on the registry are indexed under Agnosia; 508 are open to participants now.

This study's planned enrollment of 75 is close to the median of 78 across 1,024 interventional studies indexed under Agnosia.

Browse Agnosia studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Multiparous women who received antenatal care, presented for vaginal delivery of uncomplicated term pregnancy of singleton fetus with engaged fetal head and cervical dilatation of at least 5 cm requiring oxytocin augmentation, and requested analgesia.

    • Age: patients between 22-45 years old.

Exclusion criteria

  • Refusal of procedure or participation in the study.

    • Patients with pre-existing or pregnancy-induced hypertension, abnormal fetal heart rate tracings, obesity, endocrinal diseases and/or diagnosed fetal abnormalities.
    • Contraindication to neuraxial block.
    • Allergy to any of the study drugs.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine Group

    participants will receive intrathecal injection of 5mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml contain 5μg dexmedetomidine(0.05ml dexmedetomidine in insulin syringe+ 0.95ml normal saline).

    Drug: Dexmedetomidine

  • Active comparator
    Fentanyl group

    participants will receive intrathecal injection of 5 mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml contain 12.5μg fentanyl(0.25ml fentanyl in insulin syringe+ 0.75ml normal saline).

    Drug: Fentanyl

  • Active comparator
    Control group

    participants will receive intrathecal injection of 5mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml normal saline

    Drug: Bupivacaine Hcl 0.5% Inj

Interventions

  • DrugDexmedetomidine

    intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine

  • DrugFentanyl

    intrathecal injection of fentanyl added to hyperbaric bupivacaine

  • DrugBupivacaine Hcl 0.5% Inj

    intrathecal injection of hyperbaric bupivacaine only

06

What researchers measure

Primary outcomes

  1. Duration of pain relief

    The duration of pain relief will be defined as the duration from intrathecal injection till the VAS became more than 4

    Time frame: Up to 6 hours after intrathecal injection

  2. analgesic onset time

    The analgesia onset time will be defined as the time from intrathecal injection until the VAS became less than 4

    Time frame: within 15 minutes after intrathecal injection

  3. maximum level of sensory block

    Temperature will be assessed using methylated soaked swabs on both sides of the body

    Time frame: 15 min after the intrathecal injection

  4. visual analogue scale (VAS) of the labour pain

    The VAS (ranging from 0 = pain-free up to 10 = worst imaginable pain) of the labour pain will be recorded before the intrathecal injection, every 5 min for the first 20 min, then every 30 min for 6 hours

    Time frame: 6 hours after intrathecal injection

  5. S1 regression time

    S1 regression time will be defined as the time from intrathecal injection to sensory regression to S1 dermatome

    Time frame: 6 hours after intrathecal injection

Secondary outcomes

  1. Maternal blood pressure

    any change more than 20% of baseline mean arterial pressure

    Time frame: 6 hours post operative

  2. Maternal heart rate

    any change more than 20% of baseline heart rate

    Time frame: 6 hours post operative

  3. Post operative nausea and vomiting

    Number of participants having post operative nausea and vomiting

    Time frame: 6 hours post operative

  4. Post operative urinary retention

    Number of participants having post operative urinary retention

    Time frame: 6 hours post operative

  5. Fetal heart sounds

    Change more than 20% of fetal heart sounds before delivery

    Time frame: from intrathecal injection till delivery

  6. Fetal APGAR score

    APGAR score (1) color, 2) heart rate, 3) reflexes, 4) muscle tone, and 5) respiration, each of which is given a score of 0, 1, or 2 at 1 and 5 minutes after delivery

    Time frame: till 5 minutes after delivery

07

Study locations

1 of 1 sites recruiting
  • Ainshams University
    Cairo, Egypt
    • ainshams university · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05998551
Lead sponsor
Ain Shams University
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 1, 2023
Primary completion
Sep 1, 2023 (estimated)
Completion
Oct 1, 2023 (estimated)
Last update
Aug 21, 2023

Study contacts

Mohamed Nagdy Rashad
Contact
mohamed.nagdy@med.asu.edu.eg
01095825826

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion